Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 71

1.

Profiling of tyrosine phosphorylation pathways in human cells using mass spectrometry.

Salomon AR, Ficarro SB, Brill LM, Brinker A, Phung QT, Ericson C, Sauer K, Brock A, Horn DM, Schultz PG, Peters EC.

Proc Natl Acad Sci U S A. 2003 Jan 21;100(2):443-8. Epub 2003 Jan 9.

PMID:
12522270
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Quantification of change in phosphorylation of BCR-ABL kinase and its substrates in response to Imatinib treatment in human chronic myelogenous leukemia cells.

Liang X, Hajivandi M, Veach D, Wisniewski D, Clarkson B, Resh MD, Pope RM.

Proteomics. 2006 Aug;6(16):4554-64.

PMID:
16858728
[PubMed - indexed for MEDLINE]
3.

ARG tyrosine kinase activity is inhibited by STI571.

Okuda K, Weisberg E, Gilliland DG, Griffin JD.

Blood. 2001 Apr 15;97(8):2440-8.

PMID:
11290609
[PubMed - indexed for MEDLINE]
Free Article
4.

Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation.

Xie S, Wang Y, Liu J, Sun T, Wilson MB, Smithgall TE, Arlinghaus RB.

Oncogene. 2001 Sep 27;20(43):6188-95.

PMID:
11593427
[PubMed - indexed for MEDLINE]
Free Article
5.

Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.

Wu J, Meng F, Kong LY, Peng Z, Ying Y, Bornmann WG, Darnay BG, Lamothe B, Sun H, Talpaz M, Donato NJ.

J Natl Cancer Inst. 2008 Jul 2;100(13):926-39. doi: 10.1093/jnci/djn188. Epub 2008 Jun 24.

PMID:
18577747
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.

Koyama N, Koschmieder S, Tyagi S, Portero-Robles I, Chromic J, Myloch S, N├╝rnberger H, Rossmanith T, Hofmann WK, Hoelzer D, Ottmann OG.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2025-31.

PMID:
16609011
[PubMed - indexed for MEDLINE]
Free Article
7.

Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells.

Parmar S, Katsoulidis E, Verma A, Li Y, Sassano A, Lal L, Majchrzak B, Ravandi F, Tallman MS, Fish EN, Platanias LC.

J Biol Chem. 2004 Jun 11;279(24):25345-52. Epub 2004 Mar 31.

PMID:
15056660
[PubMed - indexed for MEDLINE]
Free Article
8.
9.

Identification by electrospray ionization mass spectrometry of the sites of tyrosine phosphorylation induced in activated Jurkat T cells on the protein tyrosine kinase ZAP-70.

Watts JD, Affolter M, Krebs DL, Wange RL, Samelson LE, Aebersold R.

J Biol Chem. 1994 Nov 25;269(47):29520-9.

PMID:
7961936
[PubMed - indexed for MEDLINE]
Free Article
10.

Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571.

Gambacorti-Passerini C, Barni R, le Coutre P, Zucchetti M, Cabrita G, Cleris L, Rossi F, Gianazza E, Brueggen J, Cozens R, Pioltelli P, Pogliani E, Corneo G, Formelli F, D'Incalci M.

J Natl Cancer Inst. 2000 Oct 18;92(20):1641-50.

PMID:
11036109
[PubMed - indexed for MEDLINE]
Free Article
11.

BCR-ABL-induced adhesion defects are tyrosine kinase-independent.

Wertheim JA, Forsythe K, Druker BJ, Hammer D, Boettiger D, Pear WS.

Blood. 2002 Jun 1;99(11):4122-30.

PMID:
12010816
[PubMed - indexed for MEDLINE]
Free Article
12.
13.

A prototype antibody microarray platform to monitor changes in protein tyrosine phosphorylation.

Gembitsky DS, Lawlor K, Jacovina A, Yaneva M, Tempst P.

Mol Cell Proteomics. 2004 Nov;3(11):1102-18. Epub 2004 Sep 8.

PMID:
15358805
[PubMed - indexed for MEDLINE]
Free Article
14.

Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.

Koch A, Scherr M, Breyer B, Mancini A, Kardinal C, Battmer K, Eder M, Tamura T.

Oncogene. 2008 Aug 7;27(34):4678-89. doi: 10.1038/onc.2008.107. Epub 2008 Apr 21.

PMID:
18427551
[PubMed - indexed for MEDLINE]
15.

Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line.

Matulonis U, Salgia R, Okuda K, Druker B, Griffin JD.

Exp Hematol. 1993 Oct;21(11):1460-6.

PMID:
8405226
[PubMed - indexed for MEDLINE]
16.

Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line.

Ricci C, Scappini B, Divoky V, Gatto S, Onida F, Verstovsek S, Kantarjian HM, Beran M.

Cancer Res. 2002 Nov 1;62(21):5995-8.

PMID:
12414617
[PubMed - indexed for MEDLINE]
Free Article
17.

Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).

Beran M, Cao X, Estrov Z, Jeha S, Jin G, O'Brien S, Talpaz M, Arlinghaus RB, Lydon NB, Kantarjian H.

Clin Cancer Res. 1998 Jul;4(7):1661-72.

PMID:
9676840
[PubMed - indexed for MEDLINE]
Free Article
18.

Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.

O'Hare T, Pollock R, Stoffregen EP, Keats JA, Abdullah OM, Moseson EM, Rivera VM, Tang H, Metcalf CA 3rd, Bohacek RS, Wang Y, Sundaramoorthi R, Shakespeare WC, Dalgarno D, Clackson T, Sawyer TK, Deininger MW, Druker BJ.

Blood. 2004 Oct 15;104(8):2532-9. Epub 2004 Jul 15.

PMID:
15256422
[PubMed - indexed for MEDLINE]
Free Article
19.

Differential tyrosine phosphorylation of leukemic cells during apoptosis as a result of treatment with imatinib mesylate.

Park J, Kim S, Oh C, Yoon SS, Lee D, Kim Y.

Biochem Biophys Res Commun. 2005 Oct 28;336(3):942-51.

PMID:
16157305
[PubMed - indexed for MEDLINE]
20.

Tyrosine phosphorylation of p120cbl in BCR/abl transformed hematopoietic cells mediates enhanced association with phosphatidylinositol 3-kinase.

Jain SK, Langdon WY, Varticovski L.

Oncogene. 1997 May 8;14(18):2217-28.

PMID:
9174058
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk